Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong

Abstract Introduction Lower-dose ceritinib (450 mg) once-daily with food was approved in 2018 in Hong Kong (HK) for first-line treatment of patients with anaplastic lymphoma kinase-positive (ALK +) advanced non-small cell lung cancer (NSCLC). This study examined the cost-effectiveness of ceritinib v...

Full description

Bibliographic Details
Main Authors: Herbert H. Loong, Carlos K. H. Wong, Linda K. S. Leung, Catherine P. K. Chan, Andrea Chang, Zheng-Yi Zhou, Jipan Xie, Meaghan Gibbs
Format: Article
Language:English
Published: BMC 2020-11-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Advanced non-small cell lung cancer
Anaplastic lymphoma kinase-positive
Ceritinib; cost-effectiveness
Hong kong
Online Access:http://link.springer.com/article/10.1186/s12962-020-00244-6

Internet

http://link.springer.com/article/10.1186/s12962-020-00244-6

Similar Items